Why Zura Bio Limited’s (ZURA) Stock Is Up 7.86%
As of Monday, August 24, Zura Bio Limited’s ZURA share price has surged by 7.86%, which has investors questioning if this is right time to sell.Michael Rose
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Zura Bio Limited, a clinical-stage biotechnology company, develops medicines for autoimmune and inflammatory disorders in the United States. The company develops Tibulizumab, a humanized IgG4 single-chain variable fragment bispecific antibody engineered to bind and neutralize both IL-17A and BAFF within a single therapeutic molecule, which is in Phase 2 clinical trial development. It also develops Torudokimab (ZB-880), a fully human immunoglobulin G4 monoclonal antibody targeting interleukin-33 that has completed Phase 1 clinical studies; and Crebankitug (ZB-168), a fully human immunoglobulin G1 monoclonal antibody targeting interleukin-7 receptor alpha that has completed Phase 1 clinical studies. Zura Bio Limited was founded in 2022 and is headquartered in Henderson, Nevada.
Commentary & Analysis
Why Zura Bio Limited’s (ZURA) Stock Is Up 5.15%
As of Tuesday, August 11, Zura Bio Limited’s ZURA share price has surged by 5.15%, which has investors questioning if this is right time to sell.Jenna Brashear
Why Zura Bio Limited’s (ZURA) Stock Is Up 5.90%
As of Friday, July 17, Zura Bio Limited’s ZURA share price has surged by 5.90%, which has investors questioning if this is right time to sell.Jenna Brashear
Why Zura Bio Limited’s (ZURA) Stock Is Down 6.99%
As of Friday, July 10, Zura Bio Limited’s ZURA share price has dipped by 6.99%, which has investors questioning if this is right time to buy.Cynthia McLaughlin
Why Zura Bio Limited’s (ZURA) Stock Is Down 6.90%
As of Tuesday, July 07, Zura Bio Limited’s ZURA share price has dipped by 6.90%, which has investors questioning if this is right time to buy.Rosalio Madrigal
Financial Summary
| Share Statistics | ZURA | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $563.5 | $289.2 | 38% |
|
| Shares Out (Mil) | 126.8 | 54.1 | 67% |
|
| Institutional Ownership | 84.5% | 93.1% | 52% |
|
| Float (Mil) | 51.2 | 42.2 | 47% |
|
| Beta | -0.02 | 0.94 | 6% |
|
| Avg Daily Volume (000s) | 2,179 | 451 | 85% |
|
| Price Change (52-week) |
189.7% | 59.8% | 97% |
|
| Growth | ZURA | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 14.1% | na |
|
| Net Income (5yr) | na | (10.1%) | na |
|
| EPS (5yr) | na | 15.9% | na |
|
| Dividends (5yr) | na | 0.0% | na |
|
| Cash Flow (5yr) | na | (15.6%) | na |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 3 | 3 | 3 | |
| Current EPS | ($0.203) | ($0.773) | ($0.583) | |
| Month Ago EPS | ($0.180) | ($0.723) | ($0.553) | |
| # Rev Up | 0 | 1 | 0 | |
| # Rev Down | 1 | 1 | 1 | |
| Three Months Ago EPS | ($0.180) | ($0.640) | ($0.220) | |
| Year/Year Chg | (1.9%) | (26.7%) | (15.9%) | |
| Financials | ZURA | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | na | $37 | na |
|
| Net Income (TTM) (Mil) | ($86) | ($43) | 12% |
|
| EPS (TTM) | ($1.087) | ($1.500) | 20% |
|
| Operating Cash Flow (TTM) (Mil) | ($78) | ($31) | 7% |
|
| Net Cash Flow (TTM) (Mil) | $51 | $2 | 70% |
|
| Long-Term Debt (Q1) (Mil) | $0 | $4 | 0% |
|
| Enterprise Value (Q1) (Mil) | $328 | $190 | 30% |
|
| Valuation | ZURA | Industry Median |
Percentile (All Stocks) |
|
| P/B | 2.84 | 2.84 | 63% |
|
| P/E | na | 20.4 | na |
|
| Dividend Yield | na | 0.0% | na |
|
| PEG (5yr hist) | na | 1.1 | na |
|
| Ratios | ZURA | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | na | 66.9% | na |
|
| Net Margin | na | (74.2%) | na |
|
| ROA | (46.2%) | (47.8%) | 12% |
|
| ROE | (53.1%) | (55.0%) | 15% |
|
| Liabilities to Assets | 7.6% | 29.7% | 4% |
|
| F-Score | 2 | 3 | 7% |
|
Zura Bio Limited did not pass any screens on 9/3/2026.
